Dijous 11 de juny, el Dipòsit Digital no estarà operatiu de 15:00 a 17:00 h per tasques de manteniment. Disculpeu les molèsties.
El jueves 11 de Junio, el Dipòsit Digital no estará operativo de 15:00 a 17:00 h debido a tareas de mantenimiento. Disculpen las molestias.
Thursday, Jun 11th, the Digital Repository will be unavailable due to a system update.

Document type

Article

Version

Published version

Publication date

Publication license

cc-by (c) Souto, Eliana B. et al., 2021
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/183722

Lipid Nanocarriers for Hyperproliferative Skin Diseases

Journal Title

Director/Tutor

Journal ISSN

Volume Title

Abstract

Hyperproliferative skin diseases (HSD) are a group of diseases that include cancers, pre-cancerous lesions and diseases of unknown etiology that present different skin manifestations in terms of the degree and distribution of the injuries. Anti-proliferative agents used to treat these diseases are so diverse, including 5-aminolevulinic acid, 5-fluorouracil, imiquimod, methotrexate, paclitaxel, podophyllotoxin, realgar, and corticosteroids in general. These drugs usually have low aqueous solubility, which consequently decreases skin permeation. Thus, their incorporation in lipid nanocarriers has been proposed with the main objective to increase the effectiveness of topical treatment and reduce side effects. This manuscript aims to describe the advantages of using lipid nanoparticles and liposomes that can be used to load diversity of chemically different drugs for the treatment of HSD. Keywords: lipid nanoparticles; liposomes; hyperproliferative skin diseases; antiproliferative drugs; skin cancer

Subject (English)

Citation

Citation

SOUTO, Eliana B., et al. Lipid Nanocarriers for Hyperproliferative Skin Diseases. Cancers. 2021. Vol. 13, num. 5619. ISSN 2072-6694. [consulted: 10 of June of 2026]. Available at: https://hdl.handle.net/2445/183722

Export metadata

JSON - METS

Share record